CHICAGO, IL—The weight-loss medication tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and ...

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

Total and LDL cholesterol variability over time may be a biomarker for higher dementia risk and cognitive decline.

The prevalence of obesity and overweight is extraordinarily high. Unsurprisingly, deaths related to obesity are on the rise, ...

COVID-19 “magnified” preexisting disparities for rural patients as compared with their urban counterparts, one study author ...

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

In high- and standard-risk patients CAS and TCAR look good, but some worry about skill sets, learning curves, and ...

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

The latest version of the LLM had high concordance with a multidisciplinary heart team in choosing between PCI and CABG.

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

Private equity is taking on a much larger role within cardiology, the 12th annual cardiovascular provider compensation and ...